文献速递系统性红斑狼疮

抗dsDNA抗体不同检测方法在系统性红斑狼疮静息期与活动期的比较

Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

该研究比较七种抗dsDNA抗体检测方法在狼疮肾炎活动期的表现,选出Farr与EliA两种最常阳性方法,并在152例静息期SLE、40例活动期SLE及214例疾病对照中验证。活动期两者敏感性相当,静息期EliA特异性更高;纵向分析中抗体升高对病情加重有预测价值,EliA具有无放射性、耗时少等优势。

要点

  • 活动性肾炎时Farr与EliA阳性率均为95%,活动期SLE敏感性分别为95%与93%。
  • 静息期EliA特异性91%高于Farr的53%。
  • 抗dsDNA升高25%可预测病情加重,EliA与Farr表现相当。

核心结论

  • 活动性肾炎时Farr和EliA检测抗dsDNA最常阳性且敏感性相当,两者对病情加重的预测表现相同。
  • EliA在静息期特异性更高,且不使用放射性材料、耗时更少。

研究设计与样本

  • 比较七种抗dsDNA检测方法在狼疮肾炎(n=58)中的表现。
  • 选取活动性肾炎时最常阳性的Farr与EliA两种方法,在152例静息期SLE、40例活动期SLE及214例疾病对照中检测。
  • 对伴有和不伴有病情加重的SLE患者纵向样本进行分析,确定抗体升高对病情加重的阳性预测值。

主要发现

  • 七种方法中,Farr(Siemens)与EliA(ThermoFisherScientific)结果与活动性肾炎关联最强(均为95%)。
  • 活动期SLE敏感性Farr为95%、EliA为93%。
  • 静息期特异性Farr为53%、EliA为91%。
  • 纵向分析中,抗dsDNA升高25%先于病情加重,Farr为75%、EliA为69%。
  • 无病情加重的SLE患者(n=42)中,Farr升高者10%、EliA升高者12%。

临床怎么用

  • 活动性肾炎评估可优先选用Farr或EliA检测抗dsDNA。
  • 静息期监测可考虑EliA,因其特异性更高且无放射性、耗时少。
  • 纵向监测抗dsDNA升高25%有助于预警SLE病情加重。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Auto-antibodies directed to dsDNA (anti-dsDNA) are used in diagnosis and follow-up for SLE. However, multiple assays are used. The objective of this study was to determine the best-performing assays, especially in prediction of exacerbations. METHODS: Seven assays were compared during LN (n = 58). The two assays with the most frequent positive results during active nephritis were selected and tested in 152 SLE patients with quiescent disease, 40 with active disease and 214 disease controls. Furthermore, longitudinal samples of SLE patients with and without exacerbations were examined to determine the positive predictive value of an increase for an exacerbation. RESULTS: Of seven assays, results of the Farr (Siemens) and enzyme-labelled anti-isotype assay (EliA) (ThermoFisherScientific) were foremost associated with active nephritis (both 95%). Sensitivity in active SLE was equal using Farr or EliA (95 vs 93%). In quiescent disease, the specificity of EliA was higher (Farr: 53% vs EliA: 91%). In longitudinal analyses, a 25% increase of anti-dsDNA preceded an exacerbation in 75 vs 69% (Farr vs EliA). In SLE patients without exacerbations (n = 42), a rise was seen in 10 vs 12%. Increases in anti-dsDNA occurred more often prior to nephritis (n = 17) compared with non-nephritic flares (n = 17), which was not different between both assays (Farr: 82 and 66%, respectively; EliA: 93 and 43%, respectively). CONCLUSION: Anti-dsDNA is most frequently positive using Farr and EliA during active nephritis, with comparable sensitivity. Both assays performed equally during exacerbations. However, EliA had higher specificity in quiescent disease and had several advantages, including no use of radioactive materials and less time required.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. de Leeuw K, Bungener L, Roozendaal C, et al. Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease. Rheumatology (Oxford). 2017. PMID: 28053277. doi:10.1093/rheumatology/kew462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。